Price
$7.67
Decreased by -1.41%
Dollar Volume
13.33 M
ADR%
7.57
Earnings Report Date (estimate)
Feb 21, 23 (-0.7)
Market Cap.
1.11 B
Shares Float
82.20 M
Shares Outstanding
144.21 M
Beta
0.70
Price / Earnings
-3.49
BPR
17.11
20D Range
5.86 8.44
50D Range
5.41 11.10
200D Range
5.41 17.49
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 2, 22 -0.58
Decreased by -1.75%
-0.64
Increased by +9.38%
Aug 9, 22 -0.52
Increased by +1.89%
-0.61
Increased by +14.75%
May 4, 22 -0.56
Decreased by -124.00%
-0.58
Increased by +3.45%
Feb 23, 22 -0.54
Decreased by -1.89%
-0.60
Increased by +10.00%
Nov 4, 21 -0.57
Decreased by -9.62%
-0.56
Decreased by -1.79%
Aug 4, 21 -0.53
Increased by 0.00%
-0.55
Increased by +3.64%
May 5, 21 -0.25
Increased by +50.00%
-0.46
Increased by +45.65%
Feb 25, 21 -0.53
Increased by +8.62%
-0.56
Increased by +5.36%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 49.00 K
Increased by 0.00%
-83.15 M
Decreased by -6.35%
Decreased by -169.69 K%
Decreased by -6.35%
Jun 30, 22 0.00
Decreased by -100.00%
-74.79 M
Decreased by -5.43%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 61.00 K
Decreased by -99.84%
-79.85 M
Decreased by -141.86%
Decreased by -130.90 K%
Decreased by -151.93 K%
Dec 31, 21 51.00 K
Increased by +N/A%
-74.87 M
Decreased by -9.18%
Decreased by -146.80 K%
Decreased by N/A%
Sep 30, 21 49.00 K
Increased by +N/A%
-78.19 M
Decreased by -18.11%
Decreased by -159.56 K%
Decreased by N/A%
Jun 30, 21 44.00 K
Increased by +N/A%
-70.94 M
Decreased by -16.34%
Decreased by -161.22 K%
Decreased by N/A%
Mar 31, 21 38.34 M
Increased by +N/A%
-33.02 M
Increased by +39.40%
Decreased by -86.10%
Decreased by N/A%
Dec 31, 20 0.00
Decreased by N/A%
-68.57 M
Decreased by -12.35%
Decreased by N/A%
Decreased by N/A%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.